跳至主要内容
临床试验/2025-521234-28-00
2025-521234-28-00招募中3 期

Eight weeks of low dose hCG priming in women with diminished ovarian reserve undergoing IVF/ICSI – a randomized controlled trial

Rigshospitalet4 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年6月3日最近更新:
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
80
试验地点
4
主要终点
The number of oocytes retrieved after hCG vs placebo priming

研究概览

简要总结

The aim of the study is to examine the effects of low dose hCG priming for eight weeks in women with DOR undergoing IVF/ICSI. We want to retest the findings of our pilot study (Friis Wang et al. 2023), as an increase of 50% in number of oocytes retrieved is clinically relevant.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Female, Age 18-40 (both inclusive), Regular menstrual cycle (23-35 days), 1.-
  • IVF/ICSI cycle at inclusion, AMH < 6.29 pmol/L (Elecsys® AMH assay)

排除标准

  • Uterine malformations or hydrosalpinx, Submucosal uterine myomas, Uterine polyps, Allergy to standard IVF/ICSI medication, Endometriosis stage III-IV, Preimplantation genetic testing, Testicular sperm aspiration/extraction, Known severe comorbidity

结局指标

主要结局

The number of oocytes retrieved after hCG vs placebo priming

The number of oocytes retrieved after hCG vs placebo priming

次要结局

  • Antral follicle count, AMH, number of follicles, number of fertilized eggs, number of cleaved day 2 embryos, number of good and top quality day 2 embryos, number of blastocysts, cycle cancellation rate, Reproductive hormone levels, granulosa cell receptor expression, prenancy and live birth rates

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Kristine Løssl

Scientific

Rigshospitalet

研究点 (4)

Loading locations...

相似试验